Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHMB 0.08% monotherapy versus PHMB 0.02% + propamidine 0.1% for Acanthamoeba keratitis
ISRCTN12199908Phase 3Completed
- Sponsor
- SIFI Medtech
- Start
- Aug 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in Acanthamoeba keratitis (AK) comparing PHMB 0.08% monotherapy plus placebo with PHMB 0.02% plus propamidine 0.1% (2 arms). Primary endpoint: Clinical resolution rate at 12 months. Started Aug 2017; status: completed.
02
Drugs
polihexanidepropamidine
03
Conditions
Acanthamoeba keratitis (AK)
Beyond the preview
Go deeper on ISRCTN12199908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12199908.